I spent the last two decades in the intersection of technology innovation and life science.  My experience cover all major diagnostic modalities in drug development - PET imaging at GE, precision medicine and digital biomarkers at UCB and Koneksa.

I believe the potential of digital and AI will be unlocked when they are applied to solve business problems and improve productivity.  At EPoC Science we are solving the urgent challenge of trial endpoint sensitivity and variability using technologies.